• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Landsittel Michael

    3/25/26 5:49:56 PM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DMRA alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Landsittel Michael

    (Last)(First)(Middle)
    C/O DAMORA THERAPEUTICS, INC.,
    221 CRESCENT ST, BUILDING 23, SUITE 105

    (Street)
    WALTHAM MASSACHUSETTS 02453

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/23/2026
    3. Issuer Name and Ticker or Trading Symbol
    Damora Therapeutics, Inc. [ DMRA ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Garrett Winslow, attorney-in-fact03/25/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $DMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DMRA

    DatePrice TargetRatingAnalyst
    3/25/2026$46.00Outperform
    Evercore ISI
    More analyst ratings

    $DMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jarrett Jennifer

    4 - Damora Therapeutics, Inc. (0001800315) (Issuer)

    4/1/26 5:30:23 PM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Jarrett Jennifer

    3 - Damora Therapeutics, Inc. (0001800315) (Issuer)

    4/1/26 5:24:39 PM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Winslow Garrett

    4 - Damora Therapeutics, Inc. (0001800315) (Issuer)

    3/25/26 6:09:57 PM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMRA
    SEC Filings

    View All

    Damora Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Damora Therapeutics, Inc. (0001800315) (Filer)

    3/23/26 9:00:10 AM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Damora Therapeutics Inc.

    S-8 - Damora Therapeutics, Inc. (0001800315) (Filer)

    3/20/26 4:00:31 PM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Damora Therapeutics Inc.

    10-K - Damora Therapeutics, Inc. (0001800315) (Filer)

    3/19/26 4:00:29 PM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on Damora Therapeutics with a new price target

    Evercore ISI initiated coverage of Damora Therapeutics with a rating of Outperform and set a new price target of $46.00

    3/25/26 9:37:15 AM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to four newly-hired, non-executive employees on March 24, 2026 and to its newly-hired President and Chief Executive Officer, Jennifer Jarrett, on March 30, 2026. The inducement grants were approved by Damora's Board of Directors or its independent Compensation Committee and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants made on March 24,

    3/30/26 8:00:00 AM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

    -- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named Chairman of the Board of Directors -- BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett will also serve on the company's Board of Directors. "We are excited to welcome Jen to Damora as we accel

    3/23/26 8:00:00 AM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

    -- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash equivalents as of February 28, 2026, expected to fund operations into Phase 3 development of DMR-001 -- BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (formerly Galecto, Inc.) ("Damora" or the "Company") (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced its operating and financial results for the year ended December 31, 2025, and recent corporate highlights. "At Damora Therapeuti

    3/19/26 4:10:00 PM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors

    -- Ms. Jarrett brings nearly three decades of executive leadership in biotech, tech and finance -- -- Biotech leaders Dr. Cameron Turtle and Mike Landsittel appointed to Board of Directors -- -- Peter Harwin named Chairman of the Board of Directors -- BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that its Board of Directors has appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Ms. Jarrett will also serve on the company's Board of Directors. "We are excited to welcome Jen to Damora as we accel

    3/23/26 8:00:00 AM ET
    $DMRA
    Biotechnology: Pharmaceutical Preparations
    Health Care